Skip to content
Bored Studies
RecruitingPhase 2

Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis

Novaliq GmbH · NCT07285070

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
20
US sites recruiting
6
Study start
March 16, 2026
Record last updated
July 28, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The primary objective of the study is to investigate the safety and tolerability of NOV05 eye drops at two concentrations QID in patients with active non-infectious anterior uveitis.

Being studied: Tacrolimus ophthalmic solution

Conditions: Non-infectious Anterior Uveitis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Be ≥18 years of age;
  • Provide written informed consent;
  • Be diagnosed with active non-infectious anterior uveitis requiring initiation or increase of topical steroids administration for the management of ocular inflammation;
  • Have an onset of symptoms within 4 weeks;

Exclusion Criteria

  • Have severe/serious ocular pathology in the study eye which may preclude study completion or interferes with trial assessment, in the judgement of the clinical Investigator;
  • Have a history of or a current ocular or periocular malignancy;
  • Have active intermediate or posterior uveitis in the study eye or another documented posterior segment inflammation;
  • A confirmed or highly suspicious infectious uveitis eg, CMV, Herpes simplex, Herpes zoster, syphilis, tuberculosis, lyme disease;
  • Have a known allergy or sensitivity to the IMP tacrolimus or semifluorinated alkanes (SFA);
  • Be a woman who is pregnant, nursing, or planning a pregnancy;
  • Have a condition or be in a situation (e.g. language barrier, non-cooperative, history of substance abuse) which the Investigator considers that it may put the patient at significant risk, may confound the trial results, or may significantly interfere with the patient's participation in the trial;

Recruiting US locations

  • Horizon Eye & Lasik Center

    Phoenix, AZ 85004

    Site contact: Study Coordinator · hello@doctrials.com

  • Bascom Palmer Eye Institute

    Miami, FL 33136

    Site contact: Javier Paredes · 305-326-6387 · jxp2537@med.miami.edu

  • Massachusetts Eye Research and Surgery Institution

    Waltham, MA 02451

    Site contact: Study Coordinator · +1 781-647-1431

  • Metropolitan Eye Research and Surgery Institute

    Palisades Park, NJ 07650

    Site contact: Study Coordinator · +1 201-461-3970

  • Valley Retina Institute, P.A.

    McAllen, TX 78503

    Site contact: Alexia Salas · +1 956-631-8875

  • Virginia Eye Consultants

    Norfolk, VA 23502

    Site contact: Alexandria Robinson · +1 757-493-3053

Study contacts (from the official record)

  • Alice Meides, PhD · +49 622150259 · ameides@novaliq.com
Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious… (NCT07285070) | Bored Studies